Novo Nordisk Eyes Turnaround as Oral Wegovy Challenges Eli Lilly in Weight-Loss Drug Race 
Capital One Says AML Review Led to Closure of Trump Organization Accounts 
AstraZeneca, Bristol Myers Squibb Explore Mega Merger Worth Nearly $400 Billion 
Takeda Hit With $885M Verdict Over Amitiza Generic Drug Delay Scheme 
RFK Jr. Orders Extended Hantavirus Quarantine for Cruise Passenger 
Vast Eyes Hong Kong IPO as Chinese AI Unicorn Gains Momentum 
Warner Bros. Discovery Shares Rise as Newsom Pushes Settlement in $110 Billion Merger Fight 
SpaceX Earnings Preview: Bernstein Says 4 Key Factors Will Drive Long-Term Valuation 
NIH Infectious Disease Leadership Shake-Up Raises Concerns Amid Ebola, Hantavirus Outbreaks 
BHP Port Hedland Strike Set to Proceed as Wage Talks Continue 
Palantir Stock Soars as AI Demand Drives Strong Q2 Earnings and Higher 2026 Outlook 
Boeing Stock Jumps as FAA Certifies 737 MAX-7 After Years of Regulatory Review 
BYD July Global Vehicle Sales Rise 22% as Overseas Demand Surges 
France Battles Mediterranean Wildfires as Heatwave Fuels Fire Risk 
TrumpRx Expands Discount Drug Access With 600 Generic Medications 
US-Backed Pediatric HIV Treatment Drops After Foreign Aid Changes, Study Finds 
Eli Lilly (NYSE: LLY) is reportedly in advanced discussions to acquire psychedelic drug developer AtaiBeckley, a move that could significantly strengthen the pharmaceutical giant’s neuroscience portfolio. According to a Bloomberg News report citing people familiar with the matter, the deal could be announced as early as this week.
The Indianapolis-based drugmaker is said to be negotiating an acquisition at a premium to AtaiBeckley’s current market value, which has reached approximately $2 billion after the biotech company’s shares surged more than 100% over the past year.
The potential transaction reflects Lilly’s growing interest in psychedelic-based therapies, an area that has attracted increasing attention as pharmaceutical companies search for new treatments for complex mental health conditions.
Analysts at BMO Capital Markets said the acquisition would provide Eli Lilly with a platform of rapid-acting psychedelic medicines while expanding its presence in treatment-resistant depression (TRD) and other difficult-to-treat psychiatric disorders. The brokerage maintained its "Outperform" rating on Lilly and a $1,300 price target, citing the long-term growth potential of psychedelic therapies as regulatory support continues to improve.
AtaiBeckley is developing innovative treatments for treatment-resistant depression and social anxiety disorder. Its leading drug candidate, BPL-003, is a fast-acting psychedelic nasal spray that has produced encouraging mid-stage clinical trial results and has received the U.S. Food and Drug Administration’s Breakthrough Therapy designation.
In addition to BPL-003, the company’s pipeline includes VLS-01 for treatment-resistant depression and EMP-01 for social anxiety disorder. Analysts believe these programs could provide Lilly with valuable late-stage assets and broaden its pipeline of psychiatric treatments.
The psychedelic medicine sector has gained momentum in recent years, driven by positive clinical data and the commercial success of Johnson & Johnson’s Spravato, an approved therapy for treatment-resistant depression. If completed, the acquisition would position Eli Lilly to capitalize on the growing market for innovative mental health treatments while reinforcing its long-term strategy in neuroscience and psychiatric drug development.
